Sarepta Therapeutics released the 168 week data for their exon skipping drug, eteplirsen, this morning. During a three year period, 7-13 year old boys with Duchenne (the age range of […]
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-based therapeutics, today announced data through Week 168 from Study 202, a Phase IIb open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy (DMD).
CureDuchenne Ventures LLC, a company that funds research to find a cure for Duchenne muscular dystrophy that was formed by the nonprofit CureDuchenne, announced today that they are investing $1 million in Capricor Therapeutics, a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, to advance promising research to treat heart disease associated with Duchenne muscular dystrophy.
Ì¢âÂÛÏ CureDuchenne, a national nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy, announced today that its founder and CEO Debra Miller will present at the Life Science Nation Redefining Early Stage Investments conference on January 13 in San Francisco.
Early use of available heart failure drugs slows the progressive decline in heart function before symptoms are apparent in boys and young men with Duchenne muscular dystrophy (DMD), according to a new study published online by The Lancet Neurology. – See more at: https://wexnermedical.osu.edu/mediaroom/pressreleaselisting/HeartDrugsOfferNewHopeinMuscularDystrophy#sthash.DPFZUrK6.dpuf
CureDuchenne, a national nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy, announced today that they are sponsoring a $710,000 research project with Kevin Flanigan, M.D., principal investigator at the Center for Gene Therapy at Nationwide ChildrenÌ¢âÂã¢s Hospital in Columbus, Ohio, that focuses on the development of a novel therapy for deletion mutations for Duchenne muscular dystrophy.
CureDuchenne announced today that Clay Matthews of the Green Bay Packers is featured in a new Public Service Announcement to help raise awareness about Duchenne muscular dystrophy. The PSA is part of CureDuchenneÌ¢âÂã¢s ongoing efforts to raise awareness and fund research to find a cure for Duchenne, a progressive muscle-wasting disease that impacts 1 in every 3,500 boys. Boys are usually diagnosed by the age of 5, in a wheelchair by 12 and most donÌ¢âÂã¢t survive their mid-20s. Currently, there is no cure for Duchenne.
Pfizer Inc. (NYSE:PFE) announced today enrollment of the first patient in a multicenter Phase II clinical trial of the investigational compound PF-06252616 in boys with Duchenne muscular dystrophy (DMD), a […]
A multi-center clinical study evaluating the safety & tolerability, efficacy, pharmacokinetics (what the body does to a drug) and pharmacodynamics (what a drug does to a body) of the new investigational compound, PF-06252616, in approximately 105 boys diagnosed with Duchenne Muscular Dystrophy (DMD) who are able to walk and climb stairs. This study is designed to support future potential regulatory filings.
